Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 44370 TA tablet
Drug: Placebo solution
Drug: BI 44370 TA solution
Drug: Placebo tablet

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02215018

Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 44370 tablet
Drug: BI 44370 powder for oral solution
Other: high fat breakfast

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02215746

Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/Ramipril, fixed dose combination tablet
Other: high fat, high caloric meal

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT02214966

Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia

Phase 1

Terminated

Conditions: Peripheral Arterial Disease

Interventions: Drug: BIWH 3
Drug: Placebo

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02215824

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 11634 tablet
Drug: BI 11634 drinking solution

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02214927

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 11634

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02214940

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 44370 TA

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02215759

Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Ramipril

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT02215005

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBW 2948 BS for oral inhalation
Drug: Placebo

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 91

Registration Number: NCT02214901

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Neoplasms

Interventions: Drug: BI 2536, intravenous
Drug: Gemcitabine, intravenous

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02215044

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy